The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
The product is expected to be launched by Q4 FY23.
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
KDAH Indore is a super-speciality, patient-centric, tertiary-care institution located in the Nipaniya area of Indore.
Prime Minister said that it is a huge day for health in Gujarat and congratulated everyone associated with these projects for completing them on time.
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
The existing hospital premises has the scope to further scale up the bed capacity as and when required in the future with minimal Capex.
Subscribe To Our Newsletter & Stay Updated
